Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADXS11-001 in high-risk locally advanced cervical cancer
NCT02853604Phase 3Terminated
- Sponsor
- Advaxis, Inc.
- Start
- Dec 2015
- Primary completion
- Jul 2019
- Modality
- Gene Editing, Gene Silencing, Vaccines & Immunotherapeutics
- Countries
- 14
01
Overview
A Phase 3 trial of axalimogene filolisbac in Cervical Cancer (CC), sponsored by Advaxis, Inc.. Started Dec 2015; status: terminated.
02
Drugs
axalimogene filolisbac
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT02853604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02853604.